Empowering Health care Systems and Communities for Snakebite Envenoming Control in India.

Snakebite envenoming (SBE) is a global health challenge, predominantly affecting economically disadvantaged regions. India contributes significantly to global snakebite mortality. Since 2013, the Indian Council of Medical Research (ICMR) has spearheaded efforts to combat SBE. A multi-sectoral engagement in the snakebite research projects and inputs from communities, traditional healers, and the health system have led to the creation of an Information Education and Communication (IEC) material suite, including management flowchart, information booklets, posters, and brochures, all available in local languages. These resources were broadly disseminated in high-burden regions in Maharashtra and Odisha, resulting in an approximately 10% increase in case reporting within a year. This holistic approach, engaging diverse stakeholders and addressing multiple facets of SBE, offers promise for alleviating the snakebite burden, not only in India but also in other low- and middle-income countries across South Asia, Africa, and South America, holding potential for broader positive global impact.

Snakebite Management and One Health in Asia Using an Integrated Historical, Social, And Ecological Framework.

Snakebite envenomation continues to contribute to high fatality and morbidity rates across Asia. Yet snake bite is one of many outcomes due to human-snake conflicts, which themselves are only one type of human-snake relationship among the diversity of such interactions. We propose that human-snake relationships need to be explored from a perspective integrative of history, ecology, and culture in order to adequately and holistically address snake bite. In order to contextualize this concept within a language already understood in conservation research, we characterize and develop four interconnected themes defining human-snake relationships as a social ecological system. By breaking down the multifaceted nature of human-snake relationships under a social ecological systems framework, we explore its applicability in contributing to a unified strategy, drawing from both social and natural sciences for ending the snakebite crisis.

Snakebite epidemiology and health-seeking behavior in Akonolinga health district, Cameroon: Cross-sectional study.

BACKGROUND: Snakebite envenoming causes 81,000-138,000 annual human deaths and pain, terror, or disability in 4.5-5.4 million victims. Accurate community-based epidemiological data is scarce. Our objective was to assess snakebite incidence, mortality, and health-seeking behavior, in an affected health district of Cameroon. METHODS: We conducted a cross-sectional multicluster household survey in Akonolinga health district, Centre Region, Cameroon, from October to December 2016. Using probability-proportional-to-size, 20 villages were randomly selected, then, all inhabited households were systematically selected. Annual incidence and adjusted odds-ratio for predictors were estimated. FINDINGS: Among the 9,924 participants, 66 suffered a snakebite during the past year: the resulting incidence is 665 (95%CI: 519-841) per 100,000 inhabitants per year. Victims were aged 5-75y (median: 34y), 53% were male and 57% farmer-cultivators. Two children died (case-fatality rate: 3%); 39 (59%) presented severity signs, including 2 (3%) neurotoxic syndromes, 20 (30%) systemic digestive syndromes, and 17 (26%) severe cytotoxic syndromes. Non-severe cases included 20 (30%) mild cytotoxic syndromes and 7 (11%) dry bites. Only two victims (3%) received antivenom. 59 (89%) used family traditional practices, 25 (38%) traditional healers, and 31 (47%) consulted health facilities. Median delays to these three care-options were 5, 45, and 60 minutes, respectively. Traditional treatments included incisions (n = 57; 86%), tourniquets (n = 51; 77%) and black-stones (n = 44; 67%). The two last procedures were also used in health facilities (n = 18). Consulting traditional healers was associated with severity (adjusted-OR: 19.6 (2.5-156), p = 0.005) and complications (aOR: 17.3, 2.4-123, p = 0.004). Long-term disabilities were subjective psychological trauma (n = 47; 71%), finger amputation (n = 1; 2%), ankylosis (n = 1; 2%) and chronic pain (n = 1; 2%). CONCLUSIONS: We observed alarming levels of snakebite incidence, mortality, antivenom scarcity, and use of traditional medicine. It could represent several thousands of victims at national level. We suggested conducting a country-wide study, and improving antivenom supply, first-aid training, for traditional healers and health professionals.

Acción antiofídica de extractos de Myrsine guianensis, Jatropha curcas y Zanthoxylum monogynum / Antiophidic activity of extracts from Myrsine guianensis, Jatropha curcas and Zanthoxylum monogynum

Objetivo: evaluar la inhibición de los venenos de las serpientes Bothrops alternatus y Bothrops moojeni por los extractos vegetales de Jatropha curcas, Myrsine guianensis y Zanthoxylum monogynum, en relación con las actividades coagulante, fosfolipasa y hemorrágica. Métodos: Los extractos vegetales se obtuvieron a partir del liofilizado de hojas de Jatropha curca, Myrsine guianensis y Zanthoxylum monogynum. Se realizaron ensayos de inhibición in vitro con un grupo de control positivo (10 μg de veneno crudo), grupos experimentales que recibieron una mezcla del veneno con cada uno de los extractos, en concentraciones de 5 a 500 μg y un grupo de control negativo (500 μg de extracto). Se realizaron ensayos in vivo con grupos de ratones Balb/c (n = 4). A los ratones del grupo de control positivo se les inyectó solamente el veneno (25 μg); a los de los grupos experimentales, una mezcla del veneno con cada uno de los extractos, en concentraciones de 25 a 500 μg; y a los del grupo de control negativo, solamente extracto (500 μg). Resultados: Jatropha curcas y Myrsine guianensis inhibieron significativamente la actividad fosfolipasa a partir de la proporción 1:0,5 (veneno:extracto). Por otro lado, las actividades coagulante y hemorrágica, fueron inhibidas expresivamente a partir de las proporciones 1:1 y 1:5 con Myrsine guianensis y Jatropha curcas, respectivamente. Las actividades fosfolipasa y coagulante fueron inhibidas con Zanthoxylum monogynum a partir de las proporciones 1:5 y 1:10, respectivamente. Conclusiones: Los extractos analizados inhibieron los venenos de Bothrops alternatus y Bothrops moojeni debido a la presencia de moléculas con posibles propiedades antiofídicas(AU)

Objective: Evaluate the inhibition of venoms from the snakes Bothrops alternatus and Bothrops moojeni by plant extracts from Jatropha curcas, Myrsine guianensis and Zanthoxylum monogynum in terms of coagulant, phospholipase and hemorrhagic activities. Methods: The plant extracts were obtained by lyophilization of leaves of Jatropha curca, Myrsine guianensis and Zanthoxylum monogynum. In vitro inhibition tests were performed with a positive control group (10 μg of crude venom), experimental groups receiving a mixture of the venom with each of the extracts at concentrations of 5 to 500 μg, and a negative control group (500 μg of extract). In vivo tests were performed with Balb/c mice (n = 4). The mice in the positive control group were injected only the venom (25 μg), the experimental groups received a mixture of the venom with each of the extracts at concentrations of 25 to 500 μg, and the negative control group received only extract (500 μg). Results: Jatropha curcas and Myrsine guianensis significantly inhibited phospholipase activity at a 1:0.5 (venom:extract) proportion. Coagulant and hemorrhagic activities were markedly inhibited at 1:1 and 1:5 proportions with Myrsine guianensis and Jatropha curcas, respectively. Phospholipase and coagulant activities were inhibited with Zanthoxylum monogynum at 1:5 and 1:10 proportions, respectively. Conclusions: The extracts analyzed inhibited the venoms from Bothrops alternatus and Bothrops moojeni due to the presence of molecules with possible antiophidic properties(AU)

Mortality due to snakebite and other venomous animals in the Indian state of Bihar: Findings from a representative mortality study.

BACKGROUND: Animal bites and stings contribute significantly to mortality in certain parts of the world. India accounts for the highest number of snakebites and related mortality globally. We report on mortality due to bite or sting of a venomous animal from a population-based study in the Indian state of Bihar which estimated the causes of death using verbal autopsy. METHODOLOGY/PRINCIPAL FINDINGS: Interviews were conducted for all deaths that occurred from January 2012 to March 2014 in 109,689 households (87.1% participation) covering 627,658 population in 1,017 clusters representative of the state using the Population Health Metrics Research Consortium shortened verbal autopsy questionnaire. Cause of death was assigned using the SmartVA automated algorithm. The annualized mortality rate per 100,000 population due to snakebite, scorpion sting and other animals adjusted for age, sex and urban-rural population distribution of the state; and detailed contextual information on snakebites are reported. Deaths due to bite/sting of a venomous animal accounted for 10.7% of all deaths due to unintentional injuries, with an adjusted mortality rate of 6.2 (95% CI 6.0-6.3) per 100,000 population. The adjusted snakebite mortality rate was 4.4 (95% CI 4.3-4.6) which was significantly higher in the rural areas (4.8, 95% CI 4.7-5.0) and in females (5.5, 95% CI 5.3-5.7). Snakebites accounted for 7.6% of all unintentional injury deaths across all ages but for 33.3% of the deaths in 10-14 years age group. A similar proportion of snakebite deaths occurred while sleeping (30.2%), playing (30.2%) and during field/outdoor activities (27.9%). In these cases, 8.2% people were already dead when found, 34.7% had died before treatment could be provided, and 28 (57.1%) had died post treatment among whom 46.4% had sought treatment at a health facility, 25% with a traditional healer, and the rest from both. Death before reaching a health provider, non-availability of medicines or doctor, referral patterns, and sex-differentials in the context of snakebite deaths are reported. None of the verbatim specifically mentioned anti-venom being used for treatment. The adjusted mortality rate for scorpion sting was 0.9 (95% CI 0.8-0.9). CONCLUSIONS: The findings from this large representative sample documents the magnitude of snakebite mortality in Bihar and highlight the circumstances surrounding the snakebite events that could facilitate prevention and intervention opportunities.

Overlooked issues of snakebite management: time for strategic approach.

Snakebite is a medical emergency in many parts of the world, particularly in the temperate regions. According to 2007 World Health Organization (WHO) report, there are about 5 million snakebite incidences resulting in 2.5 million envenoming, and 125,000 deaths occur annually. Most affected are the healthy individuals like children and farming populations with resource poor settings and away from health care centers in low-income countries of Africa, Asia and Latin America. In view of this, the WHO has declared snakebite as an ignored health crisis and a tropical disease. Although the death rate has reduced markedly due to anti-venom regiment, several limitations of it offer scope for better understanding of various ignored issues. Currently, snakebite therapeutics facing plethora of scientific, technological and public health challenges, including secondary/long term complications that have not been given importance so far. Because of dearth of knowledge, venom researchers and medical practitioners from affected countries worldwide should join together to accomplish this scenario. In view of this, the present review provides a broader perspective on the possible production and application of highly effective therapeutic master anti-venom, designing master diagnostic kit and also to deal with the inefficacy of anti-venom therapy against local manifestations and secondary complications of snakebite. The review demands thorough understanding of venom pharmacology, inculcating new strategies to handle and to enhance the efficacy of snakebite management and urge the governing systems of affected countries to take steps to curtail accidental debilitation and death rate of healthy individuals due to snakebite.

Snakebite envenoming from a global perspective: Towards an integrated approach.

Snakebite envenoming is a neglected public health challenge of compelling importance in many regions of the world, particularly sub-Saharan Africa, Asia, Latin America and Papua-New Guinea. Addressing the problem of snakebite effectively demands an integrated multifocal approach, targeting complex problems and involving many participants. It must comprise: (a) Acquisition of reliable information on the incidence and mortality attributable to snakebite envenoming, and the number of people left with permanent sequelae. (b) Improvements in production of effective and safe antivenoms, through strategies aimed at strengthening the technological capacity of antivenom manufacturing laboratories. (c) Increasing the capacity of low-income countries to produce specific immunogens(snake venoms) locally, and to perform their own quality control of antivenoms. (d) Commitments from regional producers to manufacture antivenoms for countries where antivenom production is not currently feasible. (e) Implementation of financial initiatives guaranteeing the acquisition of adequate volumes of antivenom at affordable prices in low-income countries. (f) Performance of collaborative studies on the safety and effectiveness of antivenoms assessed preclinically and by properly designed clinical trials. (g) Development of antivenom distribution programmes tailored to the real needs and epidemiological situations of rural areas in each country. (h) Permanent training programmes for health staff, particularly in rural areas where snakebites are frequent.(i) Implementation of programmes to support those people whose snakebites resulted in chronic disabilities. (j) Preventive and educational programmes at the community level, with the active involvement of local organizations and employing modern methods of health promotion. Such an integrated approach, currently being fostered by the Global Snake Bite Initiative of the International Society on Toxinology and by the World Health Organization, will help to alleviate the enormous burden of human suffering inflicted by snakebite envenoming.

Treatment of Bothrops alternatus envenomation by Curcuma longa and Calendula officinalis extracts and ar-turmerone

Investigou-se a eficácia do extrato de plantas no tratamento local do envenenamento botrópico. Veneno de serpentes Bothrops alternatus (1,25µg) diluído em 100µl de solução salina estéril foi inoculado (via intradérmica) entre as escápulas de 30 coelhos. Os animais foram divididos em seis grupos (tratamentos): grupo I: tratamento subcutâneo com extrato de Curcuma longa; grupo II: tratamento tópico com extrato hidroalcoólico de Curcuma longa; grupo III: tratamento tópico com ar-turmerone em vaselina; grupo IV: tratamento tópico com extrato metanólico de Curcuma longa; grupo V: tratamento tópico com pomada de Calendula officinalis e grupo VI: aplicação tópica de solução salina a 0,9 por cento (Controle). Os tratamentos foram realizados 30 minutos, 2h, 4h, 24h e 72h após a inoculação do veneno. Foram avaliados intensidade de edema local (com paquímetro), halo hemorrágico (régua com gabaritos circulares) e presença de necrose. Sete dias após a inoculação do veneno botrópico (168h) foi coletado sangue do coração, com e sem EDTA, para realização de hemograma, dosagem plasmática de fibrinogênio e dosagens séricas de proteína total, uréia e creatinina. Após as coletas de sangue, todos os animais foram anestesiados, sacrificados com inalação pelo éter etílico e necropsiados. Fragmentos de pele foram retirados para avaliação histopatológica. Os resultados obtidos mostraram que o tratamento mais eficaz para inibição da evolução do edema, necrose e hemorragia local após envenenamento com Bothrops alternatus foi a aplicação tópica de ar-turmerone.